Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Fujian Cancer Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07581834CT.gov Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Exemestane (this asset) | Fujian Cancer Hospital | P2 | CCC · 53 |
| Trastuzumab | Incepta Pharmaceuticals Ltd | P3 | BB |
| Sacubitril Valsartan | Silesian Centre for Heart Diseases | P4 | BB |
| Olaparib | AstraZeneca | P2 | BB |
| Vinorelbine Ditartrate | Sun Yat-sen University | P2 | BB |
| Capecitabine | University of Southern California | P3 | B |
| Tamoxifen | Fujian Cancer Hospital | P2/3 | B |
| Letrozole | Fujian Cancer Hospital | P2/3 | B |
| Ibuprofen | Medipol University | P3 | B |
+37 more in the Breast Disorder cohort
Other indications for Exemestane
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Positive Breast Cancer | — | P4 | BBB · 75 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Her2-Receptor Negative Breast Cancer | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Exemestane in Breast Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/exemestane-breast-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →